Realcan(SZ:002589) Xin Lang Cai Jing·2025-12-30 01:34Group 1 - On December 29, Ruikang Pharmaceutical experienced a decline of 2.94% with a transaction volume of 330 million yuan [1] - The financing data for Ruikang Pharmaceutical on the same day showed a financing purchase amount of 31.43 million yuan and a net financing purchase of 3.51 million yuan, with a total financing and securities balance of 291 million yuan [1] - The current financing balance of 291 million yuan accounts for 5.86% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of October 31, the number of shareholders for Ruikang Pharmaceutical was 72,300, a decrease of 0.82% from the previous period, while the average circulating shares per person increased by 0.83% to 18,879 shares [2] - For the period from January to September 2025, Ruikang Pharmaceutical reported a revenue of 5.407 billion yuan, a year-on-year decrease of 10.73%, and a net profit attributable to shareholders of 12.1366 million yuan, down 68.73% year-on-year [2] Group 3 - Since its A-share listing, Ruikang Pharmaceutical has distributed a total of 393 million yuan in dividends, with 36.0313 million yuan distributed over the past three years [3]